Welcome to our dedicated page for Corcept Therapeutics news (Ticker: CORT), a resource for investors and traders seeking the latest updates and insights on Corcept Therapeutics stock.
Corcept Therapeutics reports developments in cortisol modulation therapies for severe endocrinologic, oncologic, metabolic and neurologic disorders. The company markets Korlym for endogenous Cushing’s syndrome and Lifyorli, a relacorilant regimen approved with nab-paclitaxel for certain adults with platinum-resistant ovarian, fallopian tube or primary peritoneal cancer.
Recurring news includes financial results, revenue guidance, clinical data from programs such as ROSELLA, DAZALS and MOMENTUM, FDA-related updates, medical-conference presentations, publications, patent matters and distribution arrangements tied to Korlym, Lifyorli and the company’s selective cortisol modulator pipeline.
Corcept Therapeutics (NASDAQ:CORT) presented new data at the ADA 86th Scientific Sessions from its CATALYST and MOMENTUM trials in difficult-to-control type 2 diabetes and resistant hypertension.
Korlym treatment in patients with hypercortisolism led to statistically significant HbA1c and weight-related reductions, including numerically greater benefits in those receiving GLP-1 or tirzepatide, and highlighted high hypercortisolism prevalence in these cardiometabolic populations.
Corcept Therapeutics (NASDAQ:CORT) presented new Phase 3 ROSELLA overall survival data for Lifyorli (relacorilant) plus nab-paclitaxel in platinum-resistant ovarian cancer at ASCO 2026.
The combination reduced risk of death by 35% (HR 0.65; p=0.0004), with median overall survival of 16.0 months versus 11.9 months for nab-paclitaxel alone.
Prespecified subgroups, including patients with a taxane-free interval ≤6 months (HR 0.60) and those whose most recent regimen included a taxane (HR 0.67), also showed survival benefit without biomarker selection.
Lifyorli plus nab-paclitaxel received FDA approval in March 2026 for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer after one to three prior systemic regimens including bevacizumab.
The regimen is listed as a preferred option in NCCN Guidelines. In ROSELLA, safety was comparable to nab-paclitaxel alone; key warnings include neutropenia, severe infections, adrenal insufficiency, exacerbation of glucocorticoid-treated conditions and embryo-fetal toxicity. Common adverse reactions (>20%) included decreased hemoglobin, decreased neutrophils, fatigue, nausea, diarrhea, decreased platelets, rash and decreased appetite.
Corcept Therapeutics (NASDAQ:CORT) will resubmit its New Drug Application (NDA) to the FDA for relacorilant as a treatment for patients with Cushing’s syndrome.
Following a complete response letter and additional data analyses, Corcept expects a new PDUFA date approximately six months after resubmission.
Corcept (NASDAQ: CORT) reported two-year overall survival data from the Phase 2 DAZALS study of dazucorilant in 249 ALS patients. Patients receiving 300 mg showed an 87% reduction in risk of death versus placebo at two years (hazard ratio 0.13; p < 0.0001). The trial missed its primary functional endpoint.
Dazucorilant’s safety was described as acceptable, mainly transient abdominal pain; a pivotal Phase 3 is expected to start later in 2026.
Summary not available.
Corcept Therapeutics (NASDAQ: CORT) will report first quarter 2026 financial results and provide a corporate update on April 30, 2026. A conference call is scheduled for 5:00 p.m. ET / 2:00 p.m. PT. Participants must register in advance to receive a dial-in and unique access PIN. A listen-only webcast will be available and a replay will be posted on the Investors / Events tab of Corcept.com.
Corcept (NASDAQ: CORT) will present new subgroup overall survival data from the pivotal Phase 3 ROSELLA trial of Lifyorli (relacorilant) plus nab-paclitaxel in platinum-resistant ovarian cancer at ASCO 2026 on May 29, 2026.
Lifyorli was approved by the FDA in March 2026 and is listed as a preferred regimen in NCCN Guidelines for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Corcept (NASDAQ: CORT) presented final Phase 3 ROSELLA results showing Lifyorli (relacorilant) plus nab-paclitaxel reduced risk of death by 35% (HR 0.65; p=0.0004) and extended median overall survival by 4.1 months (16.0 vs 11.9 months) in platinum-resistant ovarian cancer.
The regimen also cut progression risk by 30% (HR 0.70; p=0.0076), was well tolerated versus chemotherapy alone, received FDA approval in March 2026, and was added to NCCN Guidelines as a preferred regimen.
Corcept Therapeutics (NASDAQ: CORT) presented late-breaking MOMENTUM trial data at ACC 2026 showing 27.3% prevalence of endogenous hypercortisolism among 1,086 patients with resistant hypertension (297 patients).
The results align with Corcept’s CATALYST trial and show higher prevalence (32.6%–36.6%) in high‑risk subgroups with elevated HbA1c and multi‑drug blood pressure regimens.
Corcept Therapeutics (NASDAQ: CORT) announced FDA approval on March 25, 2026 for Lifyorli (relacorilant) plus nab-paclitaxel to treat adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer after one to three prior systemic regimens, including at least one with bevacizumab.
Approval followed the 381‑patient ROSELLA trial: OS benefit of 4.1 months (16.0 vs 11.9 months; HR 0.65; p=0.0004) and PFS improvement (HR 0.70; p=0.008). Lifyorli is the first FDA‑approved selective glucocorticoid receptor antagonist; safety notes include neutropenia, infections, adrenal insufficiency and embryo‑fetal toxicity.